Acne Vulgaris - Drug Pipeline Landscape, 2023

Acne Vulgaris - Drug Pipeline Landscape, 2023

Acne Vulgaris is a skin condition that occurs when your hair follicles become plugged with oil and dead skin cells. There are a different kind of causes including genetics, fluctuating hormone levels, stress, high humidity and using oily personal care products.

Four main factors causing acne include excess oil (sebum) production, hair follicles clogged by oil and dead skin cells, bacteria and inflammation. Other causes include fluctuating hormone levels, air pollution and certain weather conditions and some medications.

Symptoms of acne vulgaris include Whiteheads, blackheads, small red, tender bumps, pimples , large, solid, painful lumps under the skin, painful, pus-filled lumps under the skin.

Healthcare provider can diagnose acne during a skin exam. The doctor may require to confirm significant stress if the person is going through or if have a family history of acne, all of which are risk factors. Women may also be asked about their menstrual cycles.

Treatment of acne majorly includes topical and oral medications. Topical medication include retinoids, antibiotics, azelaic acid and salicylic acid, and dapsone. Oral medications include oral contraceptives, antibiotics, anti-androgen agents etc.

There are a number of clinical trials currently ongoing in acne drug development. These trials are investigating a variety of potential new treatments for acne, including new drugs, new formulations of existing drugs, and new delivery methods for existing drugs. Some of the most promising trials are investigating new drugs that target specific bacteria associated with acne, as well as new formulations of existing acne drugs that improve their efficacy and safety.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Acne Vulgaris treatment such as IDP-126, BTX 1503, GT 20029, and others. Key players involved in the development of therapies to treat acne vulgaris are Bausch Health Americas, Inc, Novan, Inc, Biofrontera Bioscience GmbH, BioPharmX, Inc, Dermata Therapeutics and others. Five drugs are under late-stage Phase III clinical trials and twelve drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Dermata is on track to request an End of Phase II meeting with the FDA for DMT310 for the treatment of acne in the first quarter of 2023.

In November 2022, Kintor announced the completion and top-line results for its phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne in China. GT20029 demonstrated the good safety, tolerability and pharmacokinetics of GT20029 in healthy subjects.

Report Highlights

Global Insight Services, "Acne Vulgaris - Drug Pipeline Landscape, 2023" report provides an overview of the Acne Vulgaris pipeline drugs. This report covers detailed insights on Acne drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acne pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.